A
Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
NASDAQ:AQST
Price:
3.235 USD
1.09%
Market Closed
Updated:
May 16, 2024
Aquestive Therapeutics Inc
Operating Expenses
|
Aquestive Therapeutics Inc
Operating Expenses Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Operating Expenses
-$50.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Expenses
-$35.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Expenses
-$24.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Expenses
-$28.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Expenses
-$39.8B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Expenses
-$17.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
See Also
What is Aquestive Therapeutics Inc's Operating Expenses?
Operating Expenses
-50.5m
USD
-50.5m
USD
Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Operating Expenses amounts to -50.5m USD.
What is Aquestive Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
14%
14%
Over the last year, the Operating Expenses growth was 21%. The average annual Operating Expenses growth rates for Aquestive Therapeutics Inc have been 12% over the past three years , 14% over the past five years .
You don't have any saved screeners yet
